罗伯特·肯尼迪年轻要求FDA审查堕胎药物米菲普里斯的安全问题. Robert F. Kennedy Jr. asks FDA to review abortion drug mifepristone over safety concerns.

Robert F. Kennedy Jr.已要求林业发展局在一项新研究显示严重不良事件发生率高于以前报告的比率后,审查堕胎的药物mifeprístone。 Robert F. Kennedy Jr. has requested the FDA to review the abortion drug mifepristone after a new study suggested higher rates of serious adverse events than previously reported. 该研究被一些人批评为有缺陷,声称将近11%的使用者经历了严重的并发症,而林业发展局报告的比例不到0.5%。 The study, criticized as flawed by some, claims nearly 11% of users experienced severe complications, compared to the FDA’s reported rate of under 0.5%. 这项请求是在南卡罗来纳州最高法院维持一项为期六周的禁止堕胎禁令后提出的,并引发了关于该药物的安全和可获得性的辩论。 This request follows South Carolina's Supreme Court upholding a six-week abortion ban and has sparked debate over the drug's safety and accessibility.